On January 28, Dylan Kennett, from DLA Piper’s corporate team and co-lead of the Global Cannabis practice, joined a panel debate at the Cannabis Investor Summit in Odense, Denmark. DLA Piper is proud to be a partner on this summit hosted by Invest in Odense, Invest in Denmark and Novo Nordisk Engineering (NNE).

DLA Piper’s Danish offices have been very active in the medicinal cannabis sector since the introduction of Denmark’s medicinal cannabis pilot program in 2018. Jan Snogdal and Ulrik Bangsbo Hansen having advised the likes of medicinal cannabis companies Atlas Growers and Wundr on their activities and expansions in Denmark.

Dylan was invited by DLA Piper Denmark, Novo Nordisk Engineering and Invest Denmark to speak at the conference to explain to investors why this market is an interesting one to invest in and the potential pitfalls, but also the benefits, both financially and to the public at large. The event was attended by over 150 different stakeholders to learn more about the industry and DLA Piper was the only law firm presenting on the panels.

“We see Denmark as a key jurisdiction in the growth of the European medicinal cannabis market. With a strong background in pharma, agriculture and a talented and educated workforce, it is poised to do well, provided the investment in the industry follows. The government introduced a forward thinking medicinal programme and we understand that at least 25 companies are now in various stages of development in Denmark, but particularly around Odense on the island of Fyn/Funen, due to its strong ties to agriculture. Denmark is a key focus for the European cannabis practice, as it is seen as one of the areas of potential growth to service not only the Danish market but also other EU markets, such as Germany, as Europe liberalizes further. We are therefore interested to see how the market develops and how we can assist multi-nationals and domestic companies operating in Denmark." – Dylan Kennett, DLA Piper